Johnson & Johnson (J&J) has reported data from the Phase III ICONIC-LEAD trial’s subgroup analysis evaluating icotrokinra in ...

In the Phase III ICONIC-LEAD trial, 75% of adolescents with moderate-to-severe plaque psoriasis treated with icotrokinra ...

Less than a quarter of patients diagnosed with mild psoriasis had a body surface area of less than 3% at the time of diagnosis.

Step-by-step micro-lessons on the best ways to prevent skin flare-ups and avoiding known triggers so you can get back to feeling comfortable in your skin. Best part: it’s free! Amanda Caldwell ...

Protagonist and Johnson & Johnson report positive Phase 3 data on icotrokinra in adolescent plaque psoriasis, showing high ...

Recent research captures more evidence on the psoriasis–type 2 diabetes link and attempts to pinpoint the possible genetic and pathophysiologic mechanisms underlying this connection. This study ...

According to the company, continued skin clearance improvement was reported ... in patients with moderate-to-severe plaque PsO. Based on the positive outcomes of the ADVANCE studies, Johnson ...

Results from the POETYK PSO-1 and POETYK PSO-2 showed that 58% and 53% respectively of patients treated with Sotyktu achieved 75% skin clearance, versus 35% and 40% for Otezla. BMS has set a list ...

Results from the POETYK PSO-1 and POETYK PSO-2 were presented as ... more patients treated with deucravacitinib achieved 75% skin clearance and improved in a Physician’s Global Assessment ...